OpenURL Connection Search

Select item for more details and to access through your institution.

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes.
Published in:
Diabetologia, 2000, v. 43, n. 3, p. 278, doi. 10.1007/s001250050045
By:
- Raskin, P.;
- Rappaport, E. B.;
- Cole, S. T.;
- Yan, Y.;
- Patwardhan, R.;
- Freed, M. I.
Publication type:
Article
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
Published in:
Diabetes, Obesity & Metabolism, 2006, v. 8, n. 1, p. 49, doi. 10.1111/j.1463-1326.2005.00541.x
By:
- Rosenstock, J.;
- Goldstein, B. J.;
- Vinik, A. I.;
- O'Neill, M. Colleen;
- Porter, L. E.;
- Heise, M. A.;
- Kravitz, B.;
- Dirani, R. G.;
- Freed, M. I.
Publication type:
Article
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
Published in:
Diabetic Medicine, 2006, v. 23, n. 12, p. 1289, doi. 10.1111/j.1464-5491.2006.02022.x
By:
- Viberti, G.;
- Lachin, J.;
- Holman, R.;
- Zinman, B.;
- Haffner, S.;
- Kravitz, B.;
- Heise, M. A.;
- Jones, N. P.;
- O&'Neill, M. C.;
- Freed, M. I.;
- Kahn, S. E.;
- Herman, W. H.
Publication type:
Article
Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease.
Published in:
Journal of International Medical Research, 2002, v. 30, n. 4, p. 391, doi. 10.1177/147323000203000405
By:
- THOMPSON-CULKIN, K.;
- ZUSSMAN, B.;
- MILLER, A. K.;
- FREED, M. I.
Publication type:
Article
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
Published in:
Journal of Human Hypertension, 2003, v. 17, n. 1, p. 7, doi. 10.1038/sj.jhh.1001444
By:
- Bakris, G;
- Viberti, G;
- Weston, W M;
- Heise, M;
- Porter, L E;
- Freed, M I
Publication type:
Article
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Published in:
2001
By:
- Raskin, Philip;
- Rendell, Marc;
- Riddle, Matthew C.;
- Dole, Jo F.;
- Freed, Martin I.;
- Rosenstock, Julio;
- Raskin, P;
- Rendell, M;
- Riddle, M C;
- Dole, J F;
- Freed, M I;
- Rosenstock, J;
- Rosiglitazone Clinical Trials Study Group
Publication type:
journal article
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.
Published in:
2000
By:
- Wang, Andrew;
- Holcslaw, Terry;
- Bashore, Thomas M.;
- Freed, Martin I.;
- Miller, Diane;
- Rudnick, Michael R.;
- Szerlip, Harold;
- Thames, Marc D.;
- Davidson, Charles J.;
- Shusterman, Neil;
- Schwab, Steven J.;
- Wang, A;
- Holcslaw, T;
- Bashore, T M;
- Freed, M I;
- Miller, D;
- Rudnick, M R;
- Szerlip, H;
- Thames, M D;
- Davidson, C J
Publication type:
journal article

Found: 7

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes.

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease.

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.